MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
In the MOVING study should be examined, whether early therapeutic intervention with
fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a
comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual
evoked potentials (mVEP) after 6 month compared to baseline.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
NeuroCure Clinical Research Center NeuroCure Clinical Research Center, Charite, Berlin